Impact of antiplatelet treatment on colorectal cancer staging characteristics

Table 1 Number of patients in each group of the study (control - antiplatelet group), the type of therapy, tumor, nodes and metastasis stage (1-4) in each group n (%)

	No. of patients	TNM stage (mean ± SD)
Total	387
Control group	289 (74.6)	2.57 ± 0.96
Antiplatelet group	98 (25.4)	2.27 ± 0.93
Aspirin	65	2.19 ± 0.92
Clopidogrel	17
Ticlopidid	6
Dipyridamole	4
Dual therapy	6

TNM: Tumor, nodes and metastasis staging system of the American Joint Committee on Cancer.

Table 2 Incidence of colorectal cancer presenting symptoms and the distribution of cancer in the two groups of the study n (%)

	Antiplatelet group (n = 98)	Control group (n = 289)
Symptoms
Anemia	43 (43.8)	104 (35.9)
Blood loss per rectum	28 (28.5)	56 (19.3)
Obstruction/perforation	15 (15.3)	66 (22.8)
Altered bowel habits	3 (3)	29 (10)
Non-specific symptoms	4 (4)	18 (6.2)
Screening	5 (5.1)	16 (5.5)
Distribution
Right	42 (42.8)	116 (40.1)
Left	33 (33.6)	104 (35.9)
Rectum	23 (23.4)	69 (23.8)

Table 3 The incidence of each stage in each group (Antiplatelet and control group) and the comparison between the two groups n (%)

	Antiplatelet group (n = 98)	Control group (n = 289)	P value
Stage I (1)	24 (24.4)	47 (16.2)	0.0721
Stage II (2)	32 (32.6)	79 (27.3)	0.3656
Stage III (3)	34 (34.6)	114 (39.3)	0.4707
Stage IV (4)	8 (8.1)	49 (16.9)	0.033